Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Inmune Bio ( (INMB) ).
At its Annual Meeting, INmune Bio stockholders elected directors and approved several proposals, including the ratification of CBIZ CPAs P.C. as independent auditors and the approval of executive compensation plans. Additionally, the company announced a collaboration with Dr. Kirsty Dixon from Virginia Commonwealth University to study the interaction between traumatic brain injury (TBI) and Alzheimer’s disease. The study showed that INmune Bio’s XPro™ treatment significantly reduces amyloid formation and improves brain function in animal models, suggesting potential benefits for TBI patients at risk of Alzheimer’s.
The most recent analyst rating on (INMB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
INmune Bio Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The company has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform, the Natural Killer Cell Priming Platform, and CORDStrom™, all of which are involved in clinical trials targeting diseases driven by chronic inflammation and cancer.
Average Trading Volume: 295,461
Technical Sentiment Signal: Sell
Current Market Cap: $176.9M
For an in-depth examination of INMB stock, go to TipRanks’ Stock Analysis page.